Ablefy is described as an all-in-one platform for online courses, payment processing, and sales, tailored for coaches, e-teachers, and digital service providers.

ablefy

LearnDash provides a learning management system (LMS) plugin for WordPress, enabling users to create and sell online courses. The platform includes various features for course management and user engagement.

LearnDash

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly

Eli Lilly and Company

LinkedIn is the world's largest professional network with more than 1 billion members in over 200 countries and territories. Founded in 2003, the company's mission is to connect the world's professionals to make them more productive and successful. It offers a diversified business model with revenue from Talent Solutions, Marketing Solutions, Sales Solutions, and Premium Subscriptions products.

Metric
Company Name	ablefy	LearnDash	Eli Lilly and Company	LinkedIn
Symbol			LLY
MSH ID	IO:ABLEFY	COM:LEARNDASH	COM:LILLY	COM:LINKEDIN
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Commercial & Professional Services	Commercial & Professional Services	Healthcare	Technology
Industry	Technology	E-learning	Drug Manufacturers - General	Software Development
Country	DE	US	US
Stage				Private Equity
Employee Count			43K
Website	ablefy.io	learndash.com	lilly.com	123compare.me
LinkedIn
Founders

Metric
Market Cap	893.17B	838.22M
Enterprise Value
Monthly Web Traffic		1.77B
Web Traffic Growth		0.02
Valuation
Raised Capital

Metric
Revenue			34.12B
Revenue (LTM)
Revenue (NTM)
Gross Profit			27.55B
EBITDA			12.46B
Operating Income			10.33B
Net Income			5.24B
EPS			5.82
Diluted EPS			5.80
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.81
Operating Profit Margin			0.27
EBITDA Margin			0.37
Net Profit Margin			0.23
Return on Equity			0.61
Return on Assets			0.10
Return on Capital Employed			0.23

IO:ABLEFY

ablefy

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			127.25
P/B Ratio			56.57
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			27.04
EV Multiple			115.09

Metric
Days Sales Outstanding			117.94
Days Payables Outstanding			129.90
Days Inventory Outstanding			327.50
Operating Cycle			452.72
Cash Conversion Cycle			323.73
Asset Turnover			0.56

Metric
Operating Cash Flow			4.24B
Free Cash Flow			-3.15B
Cash Flow to Debt			0.17
Operating Cash Flow/Sales			0.14
Free Cash Flow Yield			-0.00

Metric
Cash & Equivalents			2.82B
Accounts Receivable			-2.45B
Inventory			5.77B
Goodwill			4.94B
Debt to Capitalization			0.70
Debt to Assets			0.35
Current Ratio			1.05
Quick Ratio			1.03

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.02
R&D to Revenue			0.27
SG&A to Revenue			0.22